These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1690477)

  • 21. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials.
    Kortmann BB; Floratos DL; Kiemeney LA; Wijkstra H; de la Rosette JJ
    Urology; 2003 Jul; 62(1):1-9. PubMed ID: 12837408
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of obstruction caused by prostatic hypertrophy with prazosin. 1-year follow-up].
    Server G; Ruiz JL; Vidal J; Gallego J; Osca JM; Jiménez Cruz JF
    Arch Esp Urol; 1991 Nov; 44(9):1037-40. PubMed ID: 1725478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Benign prostatic syndrome. Urinary urgency and micturition frequency reduced with plant preparation].
    MMW Fortschr Med; 2005 Oct; 147(40):52-3. PubMed ID: 16255520
    [No Abstract]   [Full Text] [Related]  

  • 25. Data from frequency-volume charts versus maximum free flow rate, residual volume, and voiding cystometric estimated urethral obstruction grade and detrusor contractility grade in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Van Venrooij GE; Eckhardt MD; Boon TA
    Neurourol Urodyn; 2002; 21(5):450-6. PubMed ID: 12232879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary flow rate in benign prostatic hypertrophy.
    Anikwe RM
    Int Surg; 1976 Feb; 61(2):109-11. PubMed ID: 56317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of prazosin in patients with benign prostatic obstruction.
    Hedlund H; Andersson KE; Ek A
    J Urol; 1983 Aug; 130(2):275-8. PubMed ID: 6192252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in parameters before and after alpha-1-blocker therapy for men with lower urinary tract symptoms using color doppler ultrasound urodynamics: possible application for prediction of clinical outcome.
    Watanabe Y; Yokoyama T; Ozawa H; Nishiguchi J; Nose H; Kumon H
    Urol Int; 2004; 73(3):252-7. PubMed ID: 15539846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drugs for the treatment of benign prostatic hypertrophy].
    Caprino L
    Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of patients with prostatic obstruction: correlation of flow rates with voided, residual or total bladder volume.
    Drach GW; Steinbronn DV
    J Urol; 1986 Apr; 135(4):737-40. PubMed ID: 2421016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of intravenous and infravesical administration of suramin, terazosin and BMY 7378 on bladder instability in conscious rats with bladder outlet obstruction.
    Velasco C; Guarneri L; Leonardi A; Testa R
    BJU Int; 2003 Jul; 92(1):131-6. PubMed ID: 12823397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of the effectiveness of prazosin in conservative treatment of benign prostatic hypertrophy].
    Górecki R; Krzeski T; Wasik J; Borówka A
    Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):549-51. PubMed ID: 1282713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy.
    Van Batavia JP; Combs AJ; Horowitz M; Glassberg KI
    J Urol; 2010 Feb; 183(2):724-30. PubMed ID: 20022041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study of TZP-4238 on patients with benign prostatic hypertrophy--with special reference to urodynamics].
    Park YC; Akiyama T; Kurita T; Kaneko S; Mizunaga M; Yachiku S
    Hinyokika Kiyo; 1994 Aug; 40(8):761-9. PubMed ID: 7524292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1995 Oct; 154(4):1466-9. PubMed ID: 7544845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New urodynamic model to explain micturition disorders in benign prostatic hyperplasia patients. Pressure-flow relationships in collapsable tubes, hydraulic analysis of the urethra and evaluation of urethral resistance.
    Glemain P; Buzelin JM; Cordonnier JP
    Eur Urol; 1993; 24 Suppl 1():12-7. PubMed ID: 7687552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.